Manuel Ruiz Borrego

TL;DR: Adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer and was consistent, regardless of hormone-receptor status, menopausal status, or number of high- risk factors.

TL;DR: Kalinsky et al. as mentioned in this paper showed that the potential prognostic and predictive role of recurrence score (RS) for CT benefit in postmenopausal patients with HR+, HER2-, axillary lymph node (LN)-negative BC.

TL;DR: This review tries to summarize and elucidate new concepts and knowledge related to laboratory immune findings from a translational perspective focusing on breast cancer, paying special attention to those aspects that might have more significance in clinical practice and could be useful to design successful therapeutic strategies in the future.

TL;DR: Invasive disease-free survival was significantly superior for patients with node-positive early BC who received the adjuvant standard schedule EC-T than for those who receivedThe experimental ET-X regimen, and toxicity profiles differed substantially across arms.

TL;DR: For patients with high-risk node-negative BC, the adjuvant FAC-wP regimen was associated with a small but significant improvement in DFS compared with FAC therapy, in addition to manageable toxicity, especially regarding long-term cardiac effects.